Neurology:破坏性颅颈交界区结核和抗结核治疗

2018-10-30 zyx整理 神经科病例撷英拾粹

42岁肝硬化男性,MRI可见破坏性的颅颈交界区结核。

42岁肝硬化男性,MRI可见破坏性的颅颈交界区结核。齿突、轴线椎骨骨质破坏伴不均匀积液(图A,箭),压迫脊髓(图A,*)。开始进行抗结核治疗(ATT),随访复查MRI(图B-C,箭)可见病灶逐渐消退。颅颈交界区结核极为罕见但可危及生命,见于0.3%-1%的结核性脊柱炎患者。几乎所有合并神经功能缺损的患者都需要早期外科干预。在高危手术患者中,等待ATT反应以避免手术-相关的致残和致死是值得的。


(图:A:颅颈交界区矢状位T2WI可见破坏性骨密质改变,齿突周围非均匀积液,导致脊髓明显受压;B-C:抗结核治疗后3个月,积液量和伴随的骨及骨髓变化减少;6个月后病灶完全消退)

原始出处:Philips CA1, Jayarajan TK2. Destructive craniovertebral junction tuberculosis and antituberculosis treatment. Neurology. 2018 Oct 2;91(14):668-669. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000624, encodeId=d2af20006243c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Aug 28 20:02:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254230, encodeId=e30712542306d, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Oct 31 23:02:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509904, encodeId=73a515099044a, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Oct 31 23:02:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
    2019-08-28 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000624, encodeId=d2af20006243c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Aug 28 20:02:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254230, encodeId=e30712542306d, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Oct 31 23:02:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509904, encodeId=73a515099044a, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Oct 31 23:02:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000624, encodeId=d2af20006243c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Aug 28 20:02:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254230, encodeId=e30712542306d, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Oct 31 23:02:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509904, encodeId=73a515099044a, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Oct 31 23:02:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
    2018-10-31 wgx309